ITEM VIEW

Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation

dc.contributor.authorRanderia, Shehan N.en_ZA
dc.contributor.authorThomson, Greig J. A.en_ZA
dc.contributor.authorNell, Theo A.en_ZA
dc.contributor.authorRoberts, Timothyen_ZA
dc.contributor.authorPretorius, Etheresiaen_ZA
dc.date.accessioned2019-06-26T06:32:03Z
dc.date.available2019-06-26T06:32:03Z
dc.date.issued2019-06-04
dc.identifier.citationRanderia, S. N., et al. 2019. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovascular Diabetology, 18:72, doi:10.1186/s12933-019-0870-9en_ZA
dc.identifier.issn1475-2840 (online)
dc.identifier.otherdoi:10.1186/s12933-019-0870-9
dc.identifier.urihttp://hdl.handle.net/10019.1/106289
dc.descriptionCITATION: Randeria, S. N., et al. 2019. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovascular Diabetology, 18:72, doi:10.1186/s12933-019-0870-9.en_ZA
dc.descriptionThe original publication is available at https://cardiab.biomedcentral.comen_ZA
dc.description.abstractBackground: The global burden of type 2 diabetes mellitus (T2DM), together with the presence of cardiovascular risk in this population, is reaching pandemic levels. A prominent feature of T2DM is chronic and systemic inflammation, with the accompanying presence of circulating and dysregulated inflammatory biomarkers; which in turn is associated with abnormal clot formation. Methods: Here, we investigate the correlation between abnormal blood clotting, using thromboelastography (TEG), clot ultrastructure using scanning electron microscopy (SEM) and the presence of a dysregulated inflammatory cytokine profile, by examining various circulating biomarkers. Results: Our results show that many biomarkers, across TEG, cytokine and lipid groups, were greatly dysregulated in the T2DM sample. Furthermore, our T2DM sample’s coagulation profiles were significantly more hypercoagulable when compared to our heathy sample, and ultrastructural analysis confirmed a matted and denser clot structure in the T2DM sample. Conclusions: We suggest that dysregulated circulating molecules may in part be responsible for a hypercoagulable state and vascular dysfunction in the T2DM sample. We propose further that a personalized approach could be of great value when planning treatment and tracking the patient health status after embarking on a treatment regimes, and that looking to novel inflammatory and vascular biomarkers might be crucial.en_ZA
dc.description.urihttps://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0870-9
dc.format.extent15 pages : illustrationsen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherBMC (part of Springer Nature)en_ZA
dc.subjectNon-insulin-dependent diabetesen_ZA
dc.subjectNon-insulin-dependent diabetes -- Complicationsen_ZA
dc.subjectNon-insulin-dependent diabetes -- Pathophysiologyen_ZA
dc.subjectNon-insulin-dependent diabetes -- Inflammationen_ZA
dc.titleInflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formationen_ZA
dc.typeArticleen_ZA
dc.date.updated2019-06-25T16:23:24Z
dc.description.versionPublisher's versionen_ZA
dc.rights.holderAuthors retain copyrighten_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW